Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) analogue that binds to serum albumin in vivo and is approved for once-daily treatment of diabetes as well as obesity. The aim of the present studies was to design a once weekly GLP-1 analogue by increasing albumin affinity and secure full stability against metabolic degradation. The fatty acid moiety and the linking chemistry to GLP-1 were the key features to secure high albumin affinity and GLP-1 receptor (GLP-1R) potency and in obtaining a prolonged exposure and action of the GLP-1 analogue. Semaglutide was selected as the optimal once weekly candidate. Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib(8), Arg(34)) and is derivatized at lysine 26. The GLP-1R affinity of semaglutide (0.38 ± 0.06 nM) was three-fold decreased compared to liraglutide, whereas the albumin affinity was increased. The plasma half-life was 46.1 h in mini-pigs following i.v. administration, and semaglutide has an MRT of 63.6 h after s.c. dosing to mini-pigs. Semaglutide is currently in phase 3 clinical testing.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The elimination half-life of 7 (Table 2), as measured after i.v. dose in minipigs, could be increased by nearly 40% through the replacement of the C18 diacid protractor with a C20 diacid (8), providing an even more attractive PK profile for potential once-weekly clinical administration when compared to the once-weekly GLP-1R agonist semaglutide [47].”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [47]
In the citing paper
“We estimated the required sample size to be 60 participants (30 for oral and 30 for subcutaneous semaglutide), assuming a two-sided hypothesis test with a 95% confidence level and accounting for a potential 10% loss. This estimation was based on a minimum clinically relevant difference of -10% in fat body mass at the conclusion of the follow-up (22, 23).”
From Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus (2024) · cites this paper as [22]
In the citing paper
“Semaglutide, a GLP-1 analogue with an extended half-life of approximately 1 week (which permits once-weekly subcutaneous administration), 4”
From Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (2016) · cites this paper as [4]
In the citing paper
“The long half-life of semaglutide (approximately 7.5 hours in mice, 12 hours in rats, and 183 hours in humans) makes it suitable for once-weekly administration in humans (43, 48–50).”
From The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission (2023) · cites this paper as [48]
In the citing paper
“This formulation results in slower degradation and a half-life 155 to 184 hours, allowing for once-weekly subcutaneous dosing without compromising weight loss efficacy.(11, 26)”
From Semaglutide for the treatment of obesity (2023) · cites this paper as [26]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Schuck, P. (2000) · Biophysical Journal · doi:10.1016/s0006-3495(00)76713-0 · Cited by 3,868
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Kratz, F. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.010 · Cited by 2,151
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Fatty acid binding to plasma albumin
Spector, A. A. (1975) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)36723-7 · Cited by 966
Deacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 700
Self-citationAgersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510
Fatty acid binding to human serum albumin: new insights from crystallographic studies
Curry, S., Brick, P., & Franks, N. P. (1999) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(99)00148-1 · Cited by 495
Dungan, K. M., Povedano, S. T., Forst, T., González, J. G. G., Atisso, C., Sealls, W., & Fahrbach, J. L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60976-4 · Cited by 486
Research works printed but not linked: 1
- 10.1016/s0140-6736(09)60659-0 · DOI · Paper page
Cited by
Items 501–600 of 1,000
Prolonging parathyroid hormone analog action in vitro and in vivo through peptide lipidation
Höppner, J., Noda, H., Anitha, A. K., Cheloha, R. W., Dean, T., Bruce, M., Brooks, D. J., Mannstadt, M., Bouxsein, M., Gellman, S. H., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59665-7 · Cited by 16
“The GLP-1 analog, semaglutide, thus hasa C18 diacidchain coupled to a lysine atposition 20 in the 31-amino acid peptide chain 23,24 .”
Campos, C., & Unger, J. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.1971461 · Cited by 13
“ifications increase activity at GLP-1 receptors [38,39].”
Bhushan, B., Granata, D., Kaas, C. S., Kasimova, M. A., Ren, Q., Cramer, C. N., White, M. D., Hansen, A. M. K., Fledelius, C., Invernizzi, G., et al. (2022) · Chemical Science · doi:10.1039/d1sc06844j · Cited by 16
Amatya, R., Lee, D.-H., Min, K. A., & Shin, M. C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071963 · Cited by 15
Ungewiss, J., Gericke, S., & Boriss, H. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.10.018 · Cited by 14
Solution structures of long-acting insulin analogues and their complexes with albumin
Ryberg, L. A., Sønderby, P., Barrientos, F., Bukrinski, J. T., Peters, G. H. J., & Harris, P. (2019) · Acta Crystallographica Section D Structural Biology · doi:10.1107/s2059798318017552 · Cited by 13
“The half-life of degludec is 25 h (Heise et al., 2012), while that of semaglutide is approximately one week (Lau et al., 2015).”
BackgroundHarms, M., Hansson, R. F., Carmali, S., Almeida‐Hernández, Y., Sánchez‐García, E., Münch, J., & Zelikin, A. N. (2022) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.2c00034 · Cited by 13
Semaglutide—the “new kid on the block” in the field of glucagon-like peptide-1 receptor agonists?
Guja, C., & Miulescu, R. D. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.10.09 · Cited by 14
“Semaglutide has a high degree of homology (~94%) with the human GLP-1 molecule, rendering it a human GLP-1 analogue (9).”
BackgroundLiu, L., Ruan, Z., Ung, C. O. L., Zhang, Y., Shen, Y., Han, S., Jia, R., Qiao, J., Hu, H., & Guo, L. (2023) · Diabetes Therapy · doi:10.1007/s13300-022-01336-7 · Cited by 12
“Three minor but important modifications significantly extend the half-life of semaglutide to 165 h and make it suitable to be administered on a once-weekly schedule: amino acid substitutions at position 8 (alanine to alphaaminoisobutyric acid a synthetic amino acid) and at position 34 (lysine to arginine), and acylati…”
BackgroundIncretin receptor agonism rapidly inhibits AgRP neurons to suppress food intake in mice
McMorrow, H. E., Cohen, A. B., Lorch, C. M., Hayes, N. W., Fleps, S. W., Frydman, J. A., Xia, J. L., Samms, R. J., & Beutler, L. R. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186652 · Cited by 12
“Incretin receptor agonism rapidly inhibits AgRP neurons to suppress food intake in mice liraglutide is more slowly absorbed and albumin-bound than Ex-4 and, thus, changes in neural activity are not expected on the relatively short time scale of fiber photometry recordings (22).”
Overcoming Cellular and Systemic Barriers to Design the Next Wave of Peptide Therapeutics
Hochman, J. H., Sawyer, T. K., & Duggal, R. (2021) · Methods in pharmacology and toxicology · doi:10.1007/978-1-0716-1250-7_10 · Cited by 12
Zhang, M., Zhang, Y., Peng, X., He, A., Wang, Y., Deng, Y., Cui, C., Xue, F., Wei, B., Xing, W., et al. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175107 · Cited by 12
Engineering of a Biologically Active Glycosylated Glucagon-Like Peptide-1 Analogue
Chandrashekar, C., Lin, F. W., Nishiuchi, Y., Mohammed, S. F., White, B. F., Arsenakis, Y., Yuliantie, E., Zhao, P., van Dun, S., Koijen, A., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00093 · Cited by 12
Peptide Drugs: Current Status and it's Applications in the Treatment of Various Diseases
Chandarana, C. V., Juwarwala, I., Shetty, S., & Bose, A. (2024) · Current Drug Research Reviews · doi:10.2174/0125899775295960240406073630 · Cited by 14
Katole, N. T., Salankar, H. V., Khade, A. M., Kale, J. S., Bankar, N. J., Gosavi, P. A., Dudhe, B., Mankar, N., & Noman, O. (2024) · Cureus · doi:10.7759/cureus.66280 · Cited by 25
“Also, semaglutide has a higher affinity for the GLP-1 receptor, which enhances its efficacy on GLP-1A receptors [27,28].”
BackgroundPotent and Protease Resistant Azapeptide Agonists of the GLP‐1 and GIP Receptors
Dinsmore, T. C., Liu, J., Miao, J., Ünsal, Ö., Sürmeli, D., Beinborn, M., Lin, Y., & Kumar, K. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202410237 · Cited by 12
Novel neural pathways targeted by GLP-1R agonists and bariatric surgery
Hankir, M. K., & Lutz, T. A. (2024) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-024-03047-3 · Cited by 16
“Nevertheless, AP/NTS neurons seem to be a major target of GLP-1R agonists which are more stable in the bloodstream [49, 50].”
Integration of Glucagon-Like Peptide 1 Receptor Actions Through the Central Amygdala
Duran, M., Willis, J. R., Dalvi, N., Fokakis, Z. N., VIRKUS, S., & Hardaway, J. A. (2025) · Endocrinology · doi:10.1210/endocr/bqaf019 · Cited by 13
Wong, M.-T., Lin, P.-H., Lin, W., Peng, C., Wright, J. D., Lee, H.-J., Chu, H., Lim, C., & Chang, T. W. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02153 · Cited by 13
Østergaard, S., Jessen, C., Paulsson, J. F., Kasimova, M. A., Conde‐Frieboes, K. W., Straarup, E. M., Skyggebjerg, R. B., Ynddal, L., Sanfridson, A., Wulff, B. S., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adq6392 · Cited by 16
Zeng, Q., Gong, Y., Jiao, W., Xu, J., Chen, X., Xu, R., Liu, Y., Liang, X., Li, G., Liu, J., et al. (2025) · Science Advances · doi:10.1126/sciadv.adv8734 · Cited by 15
“Notably, semaglutide exhibited an extremely long circulation half-life (nearly 7 days) because of its strong affinity to the plasma albumin ( 64 , 65 ).”
Backbone Protecting Groups for Enhanced Peptide and Protein Synthesis
Paravizzini, S. J., Haugaard‐Kedström, L. M., Hutton, C. A., & Karas, J. A. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202509939 · Cited by 17
Oral Treatment of Obesity by GLP-1 and Its Analogs
Holler, N., Ruseska, I., Schachner-Nedherer, A.-L., Zimmer, A., & Petschacher, C. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17121596 · Cited by 13
Cui, X., Meng, Q., Chu, Y., Gu, X., Tang, Y., Zhou, F. L., Fei, Y., Fu, J., & Han, J. D. J. (2016) · RSC Advances · doi:10.1039/c6ra22648e · Cited by 12
Yang, Y., Tian, A., Wu, Z., Wei, Y., Hu, X., & Guo, J. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/6623379 · Cited by 16
“GLP-1 receptor agonists have recently been confirmed to promote glucose control and body weight loss [7].”
BackgroundZhang, J., Dong, Y., Ju, D., & Feng, J. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116291 · Cited by 12
Hao, Y., Wei, M., Zhang, N., & Zhang, X. (2022) · Bioengineered · doi:10.1080/21655979.2022.2031418 · Cited by 13
“Circulatory half-life protraction of the latest generation of GLP-1RAs is achieved by fatty acid conjugation and resultant binding to albumin (Semaglutide), or by covalent linkage to Fc fragment of human IgG4 (dulaglutide), both of which increase effective molecular size sufficiently to virtually abolish clearance by…”
BackgroundSani, E., Prato, G. D., Zenti, M. G., Bordugo, A., Trombetta, M., & Bonora, E. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530322666220509225637 · Cited by 14
Hu, S., Gu, S., Qi, C., Wang, S., Qian, F., Shi, C., & Fan, G. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14881 · Cited by 12
“The half-life of SEMA is prolonged by adding a fatty diacid chain and two amino acid substitutions to modify its GLP-1 moiety to achieve once-weekly dosing because these modifications enhance binding to albumin and inhibit degradation by dipeptidyl peptidase-4.(10) According to the SUSTAIN 7 trial, SEMA had greater ef…”
MethodImproving Stability Enhances In Vivo Efficacy of a PCSK9 Inhibitory Peptide
Zhang, Y., Wang, L., Tombling, B. J., Lammi, C., Huang, Y., Li, Y., Bartolomei, M., Hong, B., Craik, D. J., & Wang, C. K. L. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c08029 · Cited by 15
Ohkawachi, K., Anzaki, K., Kobayashi, D., Kyan, R., Yasuda, T., Denda, M., Harada, N., Shigenaga, A., Inagaki, N., & Otaka, A. (2023) · Chemistry - A European Journal · doi:10.1002/chem.202300799 · Cited by 12
Surface-mediated spontaneous emulsification of the acylated peptide semaglutide
Li, Q., Tangry, V., Allen, D. P., Seibert, K. D., Qian, K. K., & Wagner, N. J. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2305770121 · Cited by 12
“SMG. SMG consists of 31 amino acids in the main peptide chain whose sequence is available elsewhere (38).”
BackgroundWu, Y., Chen, Y., Corner, T. P., Nakashima, Y., Salah, E., Li, Z., Zhang, L., Yang, L., Tumber, A., Sun, Z., et al. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202410438 · Cited by 15
Gomaa, M. S., Alturki, M. S., Tawfeeq, N., Hussein, D. A., Pottoo, F. H., Khzem, A. H. A., Sarafroz, M., & Abubshait, S. A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16121607 · Cited by 14
Das, A., Geetha, K. M., & Hazarika, I. (2019) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-019-09927-y · Cited by 12
Half-life extension of peptidic APJ agonists by N-terminal lipid conjugation
Reed, A. B., Lanman, B. A., Holder, J. R., Yang, B. H., Ma, J., Humphreys, S. C., Wang, Z., Chan, J. C. Y., Miranda, L. P., Swaminath, G., et al. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127499 · Cited by 12
Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
Viljoen, A., & Bain, S. C. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1642 · Cited by 11
“It is a much smaller compound approximately 4 kilo-Dalton (kDa) compared to Dulaglutide (which is approximately 63 kDa) and this may explain its superiority over the larger once weekly compounds [27,28].”
Molecular Representations in Machine-Learning-Based Prediction of PK Parameters for Insulin Analogs
Einarson, K. A., Bendtsen, K. M., Li, K., Thomsen, M., Kristensen, N. R., Winther, O., Fulle, S., Clemmensen, L. K. H., & Refsgaard, H. H. F. (2023) · ACS Omega · doi:10.1021/acsomega.3c01218 · Cited by 11
Urva, S., Levine, J. A., Schneck, K. B., & Tang, C. C. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2322072 · Cited by 12
“26,39 Hence, these drugs would remain in systemic circulation after treat-ment is stopped.”
BackgroundHampton, J. T., Dobie, C. R., Coleman, D. D., Cherif, M., Das, S. K., & Liu, W. R. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.4c00725 · Cited by 13
Advances in Homing Peptide Targeted Therapies
Xian, X., Ren, Q., Du, H., Qi, Y., & Yan, J. (2025) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-024-10682-y · Cited by 11
“Liraglutide represented a signifi - cant improvement in GLP-1 with an extended IV half-life of 8–10 h and once-daily administration (Lau et al. 2015).”
Liu, Y., Li, Z., Xu, X., Zou, Y., Zhang, M., Chen, Y., Zhu, W., & Han, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1529652 · Cited by 11
“Semaglutide, a long-acting GLP-1A agonist, has received FDA approval for the treatment of T2DM characterized by inadequate glycemic control (Lau et al., 2015).”
Herbster, L., Pander, G., Böhmann, M. B., Eisenzapf, T., Wohlfart, S., Mühlberg, E., Mier, W., Fricker, G., & Uhl, P. (2025) · Nano Select · doi:10.1002/nano.70010 · Cited by 13
“Semaglutide (Ozempic, Wegovy) is a GLP-1 analog with amino acid sequence modifications and an additional conjugation to a fatty di-acid [32].”
Development of a Long-Acting Interleukin-11 Antagonist for the Treatment of Renal Fibrosis
Pang, N., Zhao, N., An, C., Li, K., Li, P., Wang, N., Li, J., Cheng, X., Zheng, N., Guo, D. M., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c03185 · Cited by 11
Gut microbiota mediates semaglutide attenuation of diabetes-associated cognitive decline
Qi, L., Kang, H., Zeng, F., Zhan, M., Huang, C., Huang, Q., Lin, L., He, G., Liu, X., Liu, X., et al. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00615 · Cited by 13
“Compared to native GLP-1, semaglutide has a similar ability to activate the GLP-1 receptor, but its half-life is longer due to its resistance to dipeptidyl peptidase IV [29].”
AI‐Driven De Novo Design of Ultra Long‐Acting GLP‐1 Receptor Agonists
Wei, T., Ma, J., Cui, X., Lin, J., Zheng, Z., Cheng, L., Cui, T., Lin, X., Zhu, J., Ran, X., et al. (2025) · Advanced Science · doi:10.1002/advs.202507044 · Cited by 12
Semaglutide - properties, action and chromatographic analysis
Wasilewska, B., & Petruczynik, A. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01711-8 · Cited by 13
“The volume of distribution was reported at 0.102 L/kg, with a body clear - ance of 0.0016 L/h/kg for semaglutide [ 55 ].”
InfluentialPharmacotherapy for Obesity: Recent Updates
Fredrick, T. W., Camilleri, M., & Acosta, A. J. (2025) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s497904 · Cited by 33
“146,147 The STEP trials were the pivotal trials evaluating semaglutide for obesity.”
Semaglutide in a real-world outpatient setting: discontinuation patterns and weight maintenance
Brufani, C., & Morviducci, L. (2025) · Obesity and Endocrinology · doi:10.1093/obendo/wjaf011 · Cited by 11
Tinsley, I. C., Borner, T., Swanson, M. L., Chepurny, O. G., Doebley, S. A., Kamat, V., Sweet, I. R., Holz, G. G., Hayes, M. R., Jonghe, B. C. D., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00185 · Cited by 11
Design of Potent and Proteolytically Stable Biaryl-Stapled GLP-1R/GIPR Peptide Dual Agonists
Yang, Y., Lee, C., Reddy, R. R., Huang, D. J., Zhong, W., Nguyen-Tran, V. T. B., Shen, W., & Lin, Q. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00175 · Cited by 12
OXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetes
Melander, S. A., Kayed, A., Andreassen, K. V., Karsdal, M. A., & Henriksen, K. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176215 · Cited by 11
Zhang, C., Yang, X., Wu, L., Liu, F., Dong, K., Guo, C., Gong, L., Dong, G., Shi, Y., Gu, Z., et al. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00054 · Cited by 11
Development of Zalfermin, a Long-Acting Proteolytically Stabilized FGF21 Analog
Sass‐Ørum, K., Tagmose, T. M., Olsen, J., Sjölander, A., Wahlund, P., Han, D., Vegge, A., Reedtz‐Runge, S., Wang, Z., Gao, X., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00391 · Cited by 12
Self-citationHan, J. D. J., Meng, T., Chen, X., Han, Y., Fu, J., Zhou, F. L., Fei, Y., & Li, C. (2019) · The FASEB Journal · doi:10.1096/fj.201801479r · Cited by 11
Novel approaches to anti-obesity drug discovery with gut hormones over the past 10 years
Rose, F., Bloom, S. R., & Tan, T. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1646243 · Cited by 11
“introduction of a flexible spacer to support reversible albumin binding [58].”
BackgroundAnaphylaxis to Bovine Serum Albumin Tissue Adhesive in a Non–Meat-Allergic Patient
Hilger, C., Clark, E., Swiontek, K., Chiriac, A. M., Caimmi, D. P., Demoly, P. M., & Bourrain, J. ‐. (2020) · Journal of Investigational Allergology and Clinical Immunology · doi:10.18176/jiaci.0522 · Cited by 11
Giansanti, M., Gabrieli, A. D., Prete, S. P., Ottone, T., Divona, M. D., Karimi, T., Ciccarone, F., Voso, M. T., Graziani, G., & Faraoni, I. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.121.000537 · Cited by 13
Han, C., Sun, Y., Yang, Q., Zhou, F. L., Chen, X., Wu, L., Sun, L., & Han, J. D. J. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00995 · Cited by 12
Conformationally Constrained Peptides with High Affinity to the Vascular Endothelial Growth Factor
Guryanov, I., Korzhikov-Vlakh, V. A., Bhattacharya, M., Biondi, B., Masiero, G., Formaggio, F., Tennikova, T. B., & Urtti, A. O. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00219 · Cited by 11
Niu, J., Cederstrand, A. J., Eddinger, G. A., Yin, B., Checco, J. W., Bingman, C. A., Outlaw, V. K., & Gellman, S. H. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.1c13717 · Cited by 13
GLP‐1 rescued gestational diabetes mellitus‐induced suppression of fetal thalamus development
You, L., Deng, Y., Li, D., Lin, Y., & Wang, Y. (2022) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23258 · Cited by 11
Semaglutide injection for the treatment of adults with type 2 diabetes
Chudleigh, R. A., & Bain, S. C. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1776108 · Cited by 13
Bolli, G. B., Porcellati, F., & Meier, J. J. (2020) · Diabetes Care · doi:10.2337/dci20-0038 · Cited by 11
“currently not available for treatment and similar effects still must be shown with other long-acting GLP-1 RAs that are commercially available, such as liraglutide (17), dulaglutide (18), and semaglutide (19).”
BackgroundSmall-molecule albumin ligand modification to enhance the anti-diabetic ability of GLP-1 derivatives
Sun, X., Zhang, Z., Liu, M., Zhang, P., Nie, L., Liu, Y., Chen, Y., Xu, F., Liu, Z., & Zeng, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112722 · Cited by 10
Current Status of Therapeutic Peptides for the Management of Diabetes Mellitus
Prajapati, A., Rana, D., Rangra, S., Jindal, A. B., & Benival, D. M. (2024) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-024-10590-1 · Cited by 10
“The attachment of this fatty acid chain enhances the albumin binding of semaglutide and reduces its renal clearance; hence, it prolongs the half-life of semaglutide (Lau et al. 2015; Jensen et al. 2017).”
Gokul, P. R., Apperley, L. J., Parkinson, J., Clark, K., Lund, K., Owens, M., & Senniappan, S. (2024) · Hormone Research in Paediatrics · doi:10.1159/000537921 · Cited by 15
“Semaglutide being a long-acting GLP-1 analogue has an extended half-life of 165 h compared to liraglutide due to an added albumin-binding C16 fatty acid side chain, providing greater stability and maintaining GLP-1 receptor potency [17, 19].”
Cimellaro, A., Cavallo, M., Mungo, M., Suraci, E., Spagnolo, F., Addesi, D., Pintaudi, M., & Pintaudi, C. (2024) · Medicina · doi:10.3390/medicina60091542 · Cited by 12
“Semaglutide is a GLP-1 RA with an extended half-life of approximately one week, which permits once-weekly subcutaneous administration [79].”
BackgroundKim, J., Kim, K., Lee, T. S., Cho, H., Yoo, S.-D., Kim, T., Shin, B. S., & Shin, S. (2024) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-024-00717-3 · Cited by 10
Dong, G., Gong, L., Zhang, Q., Yao, W., Shi, Y., Gu, Z., Yang, X., Gao, X., Zheng, Y., & Zhang, C. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5c00057 · Cited by 11
The expanding role of semaglutide: beyond glycemic control
Zarei, M., Sabetkasaei, M., Mozafari, M., & Zaeri, S. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01663-z · Cited by 11
“…- butyric acid substitution at position 8, macuteng it resistant to DPP-IV degradation; an 18-carbon chain added to lysine at position 26, enhancing albumin binding and extending its half-life; and a lysine-to-arginine substitution at position 34, improving stability [30 ].”
Hong, B., Kim, H., Lee, D., & Kim, K. (2025) · Pharmaceuticals · doi:10.3390/ph18071058 · Cited by 12
“Semaglutide, a potent GLP-1R agonist available in both subcutaneous and oral formulations, has shown strong efficacy in appetite suppression, increased satiety, and improvements in various metabolic parameters [8,9].”
Huang, Y., Chen, J.-C., Li, P., Hsu, M., Cheng, C., Meyerowitz‐Katz, G., & Su, P. (2025) · Communications Medicine · doi:10.1038/s43856-025-01066-4 · Cited by 11
“In contrast, Semaglutide maintains the GLP-1 (7 – 37) backbone, incorporates Aib8 and Arg34 modi fi cations, and features a shorter C-18 lipid chain at Lys26, achieving weekly dosing while targeting only GLP-1 receptors 33 .”
Glucagon-Like Peptide 1 (GLP-1) Action on Hypothalamic Feeding Circuits
Hwang, E., Portillo, B., & Williams, K. W. (2025) · Endocrinology · doi:10.1210/endocr/bqaf125 · Cited by 10
Semaglutide once-weekly: improved efficacy with a new safety warning
Coon, S. A., Crannage, E. F., Kerwin, L. C., & Guyton, J. E. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1534201 · Cited by 10
“Like other GLP-1 RAs, semaglutide selectively binds to and activates the GLP-1 receptor, leading to reduced blood glucose by delaying gastric emptying, lowering inappropriate glucagon secretion, and stimulating first- and second-phase insulin secretion in a glucose-dependent manner [11,12].”
BackgroundTherapeutic peptide delivery via aptamer-displaying, disulfide-linked peptide amphiphile micelles
Smith, J. D., Cardwell, L. N., Porciani, D., Nolla, A., Cornelison, B. T., Schulte, M. C., Gallazzi, F., Burke, D. H., Daniëls, M. A., & Ulery, B. D. (2019) · Molecular Systems Design & Engineering · doi:10.1039/c9me00092e · Cited by 10
Li, A. P. Z., & Kariyawasam, D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00098-0 · Cited by 11
In vitro cell cultures of Brunner’s glands from male mouse to study GLP-1 receptor function
Voetmann, L. M., Underwood, C. R., Rolin, B., Hansen, A. K., Kirk, R. K., Pyke, C., Knudsen, L. B., & Frederiksen, K. S. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00345.2021 · Cited by 10
Self-citationChaudhuri, D., Lu, T., Jacob, B., Abraham, S., Shankar, P., Poss, M. A., Neamati, N., & Camarero, J. A. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.05.026 · Cited by 12
Jiang, N., Su, D., Chen, D., Huang, S., Tang, C., Jing, L., Yang, C.-Y., Zhou, Z., Yan, Z., & Han, J. D. J. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01049 · Cited by 10
Mansour, N. M., El‐Masry, A. A., El‐Sherbiny, D. T., & Moustafa, M. A. (2024) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2024.124159 · Cited by 13
Glucagon-Like Peptide 1 Receptor Agonists in Psychiatry
Himmerich, H., & McElroy, S. L. (2024) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001869 · Cited by 13
Reddiar, S. B., Abdallah, M., Styles, I. K., Müllertz, O. O., & Trevaskis, N. L. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114339 · Cited by 10
Semaglutide and obesity: beyond the nutritional and lifestyle intervention?
Basile, L., Cannarella, R., Iuliano, S., Calogero, A. E., Condorelli, R. A., Greco, E. A., Aversa, A., & Vignera, S. L. (2024) · Minerva Endocrinology · doi:10.23736/s2724-6507.23.04103-9 · Cited by 11
Riehl-Tonn, V. J., Medak, K. D., Rampersad, C., MacPhee, A., & Harrison, T. G. (2024) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581241290317 · Cited by 12
“Although endogenous GLP-1 is short-lived (half-life of ~2 minutes), long-lasting GLP-1RAs have half-lives of hours to days 16 and maintain their efficacy after repeated pharmacological doses.”
BackgroundHan, J. D. J., Fu, J., Sun, L., Han, Y., Mao, Q., Liao, F., Zheng, X., & Zhu, K. (2017) · MedChemComm · doi:10.1039/c7md00471k · Cited by 10
GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus
Dahiya, L., Kaur, R., Kumar, R., Kumar, M., & Palta, K. (2019) · Current Diabetes Reviews · doi:10.2174/1573399815666190502114924 · Cited by 16
Gut Peptide Agonism in the Treatment of Obesity and Diabetes
Grandl, G., Novikoff, A., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2019) · Comprehensive physiology · doi:10.1002/cphy.c180044 · Cited by 11
A narrative review of anti-obesity medications for obese patients with osteoarthritis
Oo, W. M., Mobasheri, A., & Hunter, D. J. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2104636 · Cited by 12
“side chain with a Glu-2xOEG linker instead of a C-16 fatty acid chain with a gamma glutamate linker at position 26 [120] leading to clinically relevant superiority of Semaglutide in efficacy endpoints such as weight loss (5.”
BackgroundLiraglutide for the prevention of major adverse cardiovascular events in diabetic patients
Madsbad, S. (2019) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2019.1615444 · Cited by 12
Zhao, L., Wang, B., Wang, L., Xie, Z., Chen, Z., & Li-xia, S. (2019) · Organic & Biomolecular Chemistry · doi:10.1039/c9ob01132c · Cited by 10
Wang, M., Yao, P., Gao, M., Jin, J., & Yu, Y. (2020) · RSC Advances · doi:10.1039/c9ra10593j · Cited by 9
RetractedThe molecular basis for hydrodynamic properties of PEGylated human serum albumin
(2024) · doi:10.1016/j.bpj.2024.05.019 · Cited by 9
Ruggiero, R., Longo, M., Mascolo, A., Nuzzo, M. D., Laino, L. V., Caruso, P., D'Amato, R., Rafaniello, C., Maiorino, M. I., Esposito, K., et al. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178004 · Cited by 12
Tan, M., Shi, C., Chi, G., Su, X., Liu, F., Zhu, L., Cheng, G., Chen, X., Meng, Y., Chen, Y., et al. (2025) · Advanced Science · doi:10.1002/advs.202506841 · Cited by 14
Song, S., Jing, W., Peng, L., Liu, J., & Tai, W. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00862 · Cited by 9
Peptidic Tryptophan Halogenation by a Promiscuous Flavin‐Dependent Enzyme
Rice, A. J., Gadgil, M. G., Bisignano, P., Stein, R. A., Mchaourab, H. S., & Mitchell, D. A. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202509729 · Cited by 9
Optimization of Peptide Inhibitors of β-Klotho as Antagonists of Fibroblast Growth Factors 19 and 21
Pan, J. B., Parlee, S. D., Brunel, F. M., Li, P., Lu, W., Pérez–Tilve, D., Liu, F., Finan, B., Kharitonenkov, A., & DiMarchi, R. D. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00100 · Cited by 10
Generation of novel long-acting GLP-1R agonists using DARPins as a scaffold
Tan, H., Su, W., Zhang, W., Zhang, J., Sattler, M., & Zou, P. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121043 · Cited by 9
Machine Learning Approaches to Improve Prediction of Target‐Drug Interactions
Balatti, G. E., Barletta, P. G., D. Perez, A., Giudicessi, S. L., & Martínez‐Ceron, M. C. (2022) · Wiley eBooks · doi:10.1002/9781394167258.ch2 · Cited by 10
Metadata
- Authors
- Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., Strauss, H. M., Gram, D. X., Knudsen, S. M., Nielsen, F. S., Thygesen, P., Reedtz-Runge, S., & Kruse, T.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Global Research, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark
- Corresponding author
- Lau, Jesper
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2015-09-11
- Volume
- 58
- Issue
- 18
- Pages
- 7370-7380
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2162140339
- Cited by
- 1,105
- References
- 36
- Citations by year
- 2026: 160 · 2025: 193 · 2024: 151 · 2023: 97 · 2022: 106 · 2021: 84 · 2020: 88 · 2019: 71 · 2018: 77 · 2017: 46 · 2016: 30 · 2015: 2
- FWCI
- 44.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- semaglutide, liraglutide, glucagon-like peptide-1 analogues, GLP-1 receptor, albumin binding, weekly dosing, plasma half-life, metabolic stability, fatty acid acylation, type 2 diabetes, obesity
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Animals, Cell Line, Glucagon-Like Peptides, Half-Life, Cricetinae, Humans, Injections, Subcutaneous, Male, Mice, Obese, Models, Molecular, Structure-Activity Relationship, Swine, Swine, Miniature, Rats, Sprague-Dawley, Crystallography, X-Ray, Glucagon-Like Peptide 1, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.